Wspolczesna Onkologia-Contemporary Oncology最新文献

{"title":"The role of interleukin-6 classic and trans-signaling and interleukin-11 classic signaling in gastric cancer cells.","authors":"Josephine Runge, Christoph Garbers, Juliane Lokau","doi":"10.5114/wo.2024.142211","DOIUrl":"https://doi.org/10.5114/wo.2024.142211","url":null,"abstract":"<p><strong>Introduction: </strong>The cytokine interleukin-11 (IL-11) binds on its target cells to a membrane-bound IL-11R, which results in homodimerization of the signal-transducing β-receptor gp130. Recent studies have uncovered a pro- inflammatory role in several diseases, including different tumor entities, and mouse models have revealed a crucial role of the IL-11/IL-11R axis in gastric cancer. However, studies regarding human gastric cancer are sparse, and whether the results obtained in mouse models also hold true in the human situation is little investigated.</p><p><strong>Material and methods: </strong>We analyzed gene expression of <i>IL11RA, IL11, IL6R, IL6</i> and <i>IL6ST</i> in different gastric tumor and immune cell lines. Furthermore, we stimulated these cell lines with exogenous cytokines and determined intracellular signaling. Finally, we analyzed gene expression data of gastric tumor patients and correlated them with overall patient survival.</p><p><strong>Results: </strong>This study showed that different gastric tumor cell lines respond to IL-6 classic and trans-signaling, but only slightly to stimulation with IL-11. We observed that monocyte-like cell lines expressed high levels of IL-6R and responded to IL-6, but not to stimulation with IL-11. Using gene expression data, we found that <i>IL11RA</i> and <i>IL11</i> are not overexpressed in human gastric cancer tissue and do not correlate with patient survival. However, low <i>IL6</i> expression is associated with higher overall survival.</p><p><strong>Conclusions: </strong>We provided evidence for IL-6 but not IL-11 signaling in gastric tumor cells and demonstrated that <i>IL6</i> expression in gastric tumors is associated with overall survival of patients.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"28 2","pages":"105-113"},"PeriodicalIF":2.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480916/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142478923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychological distress and coping strategies in parents of children receiving cancer therapy in Morocco - a correlational study.","authors":"Asmaa Marrakchi, Miloud Chakit, Naoual Elmorabit, Maria El Kababri, Aboubaker El Hessni, Abdelhalim Mesfioui","doi":"10.5114/wo.2024.144134","DOIUrl":"https://doi.org/10.5114/wo.2024.144134","url":null,"abstract":"<p><strong>Introduction: </strong>Treating a child with cancer in a family is a challenge that can have an impact on mental health. The study consists of determining the prevalence of psychological distress of parents of cancer children and exploring its correlations with their coping strategies.</p><p><strong>Material and methods: </strong>The survey was conducted between March and July 2023 among parents or guardians of children with cancer. The data collection tool was a version of the general health questionnaire (GHQ12) to estimate the prevalence of psychological distress and the coping orientation to problems experienced, to explore coping strategies. The correlation between the mean GHQ12 score and adaptation strategies is assessed through bivariate analyses and multiple regression.</p><p><strong>Results: </strong>232 parents or guardians of children participated in the study. The average GHQ12 score (0-36) was 22 ±6.83. Regarding coping strategies, religion was the most frequently used strategy. The general health questionnaire score showed significant negative correlations with active coping strategies with <i>r</i> = -0.14; <i>p</i> = 0.03, and acceptance with <i>r</i> = -0.51; <i>p</i> < 0.001, and significant positive correlations with denial with <i>r</i> = 0.25; <i>p</i> < 0.001, and self-blame with <i>r</i> = 0.24; <i>p</i> < 0,001. In multivariate analysis, acceptance (β = -1.9, <i>p</i> < 0.001) and denial stra- tegy (β = 0.46, <i>p</i> = 0.02) are predictive factors of psychological distress.</p><p><strong>Conclusions: </strong>The study highlights the significant impact of coping strategies on the psychological distress experienced by parents of children undergoing cancer treatment in Morocco, by facilitating a more resilient adaptation and improved psychological well-being. These findings could form the basis for the development of culturally adapted mental health support programs for parents in simi-lar contexts.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"28 3","pages":"260-266"},"PeriodicalIF":2.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538981/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep feature extraction and fine κ-nearest neighbour for enhanced human papillomavirus detection in cervical cancer - a comprehensive analysis of colposcopy images.","authors":"Lipsarani Jena, Santi Kumari Behera, Srikanta Dash, Prabira Kumar Sethy","doi":"10.5114/wo.2024.139091","DOIUrl":"10.5114/wo.2024.139091","url":null,"abstract":"<p><strong>Introduction: </strong>This study introduces a novel methodology for classifying human papillomavirus (HPV) using colposcopy images, focusing on its potential in diagnosing cervical cancer, the second most prevalent malignancy among women globally. Addressing a crucial gap in the literature, this study highlights the unexplored territory of HPV-based colposcopy image diagnosis for cervical cancer. Emphasising the suitability of colposcopy screening in underdeveloped and low-income regions owing to its small, cost-effective setup that eliminates the need for biopsy specimens, the methodological framework includes robust dataset augmentation and feature extraction using EfficientNetB0 architecture.</p><p><strong>Material and methods: </strong>The optimal convolutional neural network model was selected through experimentation with 19 architectures, and fine-tuning with the fine κ-nearest neighbour algorithm enhanced the classification precision, enabling detailed distinctions with a single neighbour.</p><p><strong>Results: </strong>The proposed methodology achieved outstanding results, with a validation accuracy of 99.9% and an area under the curve (AUC) of 99.86%, with robust performance on test data, 91.4% accuracy, and an AUC of 91.76%. These remarkable findings underscore the effectiveness of the integrated approach, which offers a highly accurate and reliable system for HPV classification.Conclusions: This research sets the stage for advancements in medical imaging applications, prompting future refinement and validation in diverse clinical settings.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"28 1","pages":"37-44"},"PeriodicalIF":1.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11117158/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141155454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life of patients treated for stage IV breast cancer. Multidimensional assessment and examination of determining factors.","authors":"Juan Ignacio Arraras, Jose Juan Illarramendi, Ana Manterola, Uxue Zarandona, Berta Ibañez, Andrew Bottomley, Lucia Teijeira, Ignacio Visus, Susana de la Cruz, Marta Barrado, Ruth Vera","doi":"10.5114/wo.2024.147006","DOIUrl":"10.5114/wo.2024.147006","url":null,"abstract":"<p><strong>Introduction: </strong>Metastatic breast cancer (MBC) can profoundly impact patients' lives. The health-related quality of life (HRQOL) of MBC metavivors remains a paramount concern. This study exa-mined the multifaceted aspects of HRQOL in MBC metavivors.</p><p><strong>Material and methods: </strong>Ninety-eight participants with over 4 years of meta-static disease were evaluated using the European Organisation for Research and Treatment of Cancer (EORTC) questionnaires QLQ-C30, QLQ-BR42 and QLQ-BM22 alongside the Assessment of Survivor Concerns (ASC) questionnaire.</p><p><strong>Results: </strong>HRQOL scores were high (> 80/100 points) in some HRQOL areas, including role, cognitive and social functioning and breast symptoms. Moderate limitations (> 30 points) occurred in global QOL and financial impact (QLQ-C30); sexual functioning, sexual enjoyment, future perspective, breast satisfaction, upset by hair loss, skeletal symptoms, and weight gain (QLQ-BR42); and psychosocial aspects of QLQ-BM22. Worries were moderate in the two ASC factors (6.8 and 5.3) and the global scale (11.7). The multivariate model that best explains high risk of low global QOL included limiting comorbidity, financial impact, cancer worry and role functioning (<i>R</i> ² = 0.692). Patients with only bone metastases showed higher cancer and health worries (ASC scale) than patients with soft tissues and visceral sites.</p><p><strong>Conclusions: </strong>This study shows that MBC metavivors adapted well to their situation and underscores the persistent HRQOL challenges they face. In-depth analysis of the QLQ-C30 glo-bal score highlights the need to address not only medical aspects but also integrated psychosocial and economi-cal support in MBC metavivor care. HRQOL variations across metastatic sites underscore the need to tailor interventions to address site-specific challenges.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"28 4","pages":"350-357"},"PeriodicalIF":2.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11809568/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143400483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of outcome and safety profile in high-dose BEAM and Benda-EAM chemotherapy with subsequent autologous stem cell transplantation in lymphoma patients.","authors":"Kinga Krawiec, Piotr Strzałka, Olga Racińska, Marcin Kędzior, Hubert Sowul, Wojciech Salamon, Kacper Kościelny, Michał Kośny, Damian Mikulski, Agnieszka Pluta, Agnieszka Wierzbowska","doi":"10.5114/wo.2024.141794","DOIUrl":"https://doi.org/10.5114/wo.2024.141794","url":null,"abstract":"<p><strong>Introduction: </strong>Autologous hematopoietic stem cell transplantation (auto- HSCT) preceded by high-dose chemotherapy is a mainstay in relapsed/refractory lymphoma. The study aimed to compare the efficacy and adverse event profile between BEAM and Benda-EAM (BeEAM) regimens and to evaluate prognostic factors for survival in lymphoma patients undergoing auto-HSCT.</p><p><strong>Material and methods: </strong>We present a single-center retrospective analysis of 82 lymphoma patients (median age 52; IQR 38.2-62.2) who received BEAM (47.6%) or BeEAM (52.4%) followed by auto-HSCT between January 2015 and December 2021.</p><p><strong>Results: </strong>During the post-HSCT period 58% of patients experienced febrile neutropenia (51.3% vs. 64.3% in BEAM and BeEAM, respectively; <i>p</i> = 0.27), 80.5% mucositis (69.2% vs. 90.7%; <i>p</i> = 0.02), 42.5% bacteremia (50% vs. 35.7%; p = 0.26), and 18.8% pneumonia (31.6% vs. 7.1%; <i>p</i> = 0.01). Patients who received bendamustine required more platelet transfusions (<i>p</i> = 0.02). In the multivariate Cox regression model, C-reactive protein level on the first day of hospitalization (hazard ratio - HR = 1.03, 95% CI: 1.01-1.06) and days of agranulocytosis (HR = 1.15, 95% CI: 1.00-1.32) were predictors of poorer overall survival (OS), whereas hemoglobin level at the auto-HSCT was a protective factor in terms of OS (HR = 0.43, 95% CI: 0.23-0.78) and progression-free survival (PFS) (HR = 0.66, 95% CI: 0.45-0.96). The median OS since auto-HSCT was 87 months, while the median PFS was 49 months. No differences in PFS and OS between BEAM and BeEAM regimens were proven.</p><p><strong>Conclusions: </strong>Conditioning with BEAM and BeEAM regimens is associated with comparable post-transplant outcomes. The toxicity of these regimens is comparable; however, BEAM is associated with a higher risk of pneumonia, while BeEAM is associated with a higher risk of mucositis.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"28 2","pages":"158-166"},"PeriodicalIF":2.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142478917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metformin in the treatment of colorectal cancer and neuroendocrine tumours.","authors":"Karolina Daniłowska, Natalia Picheta, Barbara I Krupska, Anna Rudzińska, Oliwia Burdan, Katarzyna Szklener","doi":"10.5114/wo.2024.142553","DOIUrl":"https://doi.org/10.5114/wo.2024.142553","url":null,"abstract":"<p><p>Colorectal cancer is being detected in increasingly younger age groups, and its incidence has been on the rise in recent years. Neuroendocrine tumors have also shown an increase in occurrence despite their rarity. Neuroendocrine tumors most commonly occur in the gastrointestinal tract and lungs. Therefore, new, better, and more effective treatment methods are being sought. Metformin, a drug commonly used in the treatment of type 2 diabetes, has demonstrated its ability to reduce the incidence and increase the efficacy of chemotherapy in colorectal cancer and neuroendocrine tumors. The biguanide works by inhibiting the mammalian target of rapamycin pathway, activating 5'AMP activated protein kinase, and reducing insulin-like growth factor 1. In studies conducted on human cells and xenografts, the drug has shown its positive effects in combating these tumors by reducing proliferation, slowing the growth of cancer cells, and inhibiting metastasis. The main goal of this review is to comprehensively summarize the current state of knowledge regarding metformin in the treatment of colorectal cancer and neuroendocrine tumors.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"28 2","pages":"85-90"},"PeriodicalIF":2.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142478919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of <i>FGFR2</i> in ER-positive breast cancer is influenced by the profile of stromal gene expression: an <i>in silico</i> analysis based on TCGA data.","authors":"Julia M Sołek, Zuzanna Nowicka, Wojciech Fendler, Rafal Sadej, Hanna Romanska, Marcin Braun","doi":"10.5114/wo.2024.147003","DOIUrl":"10.5114/wo.2024.147003","url":null,"abstract":"<p><strong>Introduction: </strong>Fibroblast growth factor receptor 2 (FGFR2) activation is associated with endocrine therapy resistance in luminal breast cancer (BC) <i>in vitro</i>, but clinical evidence remains inconsistent. Given the role of FGFRs in mediating tumour microenvironment (TME) interactions, the prognostic value of FGFR2 may depend on the stromal component. This study aimed to validate the association between FGFR-related profile of the stroma and FGFR2 prognostic value in oestrogen receptor-positive invasive ductal carcinoma (IDC).</p><p><strong>Material and methods: </strong>An <i>in silico</i> gene expression analysis identified 12 stromal factors (<i>FAP, CXCL12, PDGFRA, COL1A1, HSPG2, CCL2, MMP14, S100A4, MMP9, PDGFA, MCAM, IL6</i>) forming an \"FGFR-related profile of the stroma\". A cohort of 257 ER+ IDC patients from The Cancer Genome Atlas (TCGA) was analysed. Tumours were clustered using k-means based on stromal gene expression, and Cox proportional hazards regression models were used to assess the association between FGFR2 and overall survival (OS).</p><p><strong>Results: </strong>Two clusters of ER+ IDC tumours were identified based on the stromal gene expression profile. While both clusters had similar tumour stages and hormone receptor statuses, multivariable analysis adjusted for clinical factors revealed a significant association between <i>FGFR2</i> expression and cluster assignment. In Cluster I (high expression of stromal genes), high <i>FGFR2</i> was linked to poor prognosis, whereas in Cluster II (low expression), high <i>FGFR2</i> indicated favourable prognosis. <i>FGFR1, FGFR3</i>, and <i>FGFR4</i> showed no significant prognostic value.</p><p><strong>Conclusions: </strong>Stromal profiles modulate the prognostic significance of <i>FGFR2</i> in luminal breast carcinoma, highlighting the importance of TME profiling for biomarker assessment and explaining inconsistencies in <i>FGFR2</i> studies.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"28 4","pages":"341-349"},"PeriodicalIF":2.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11809570/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143400514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The assessment of Dickkopf-1 and Dickkopf-2 protein concentration in different subtypes of non-small cell lung cancer subtypes.","authors":"Dorota Hudy, Jadwiga Gaździcka, Agata Świętek, Karolina Gołąbek, Mateusz Rydel, Damian Czyżewski, Joanna Katarzyna Strzelczyk","doi":"10.5114/wo.2024.136981","DOIUrl":"10.5114/wo.2024.136981","url":null,"abstract":"<p><strong>Introduction: </strong>Lung cancer is one of the most prevalent cancers worldwide. Dickkopf-1 (DKK-1) and -2 (DKK-2) are important proteins for the regulated Wnt signalling pathway. Alternations in the Wnt pathway are associated with tumour progression. The aim of the study was to analyse the concentration of DKK-1 and DKK-2 in tumour and matched non-tumour (NT) samples of 65 patients with non-small cell lung cancer (NSCLC), including 3 subtypes: adenocarcinoma (AC), squamous cell carcinoma (SCC), and large cell carcinoma (LCC).</p><p><strong>Material and methods: </strong>The protein concentration was measured by enzyme-linked immunosorbent assay (ELISA) in homogenates.</p><p><strong>Results: </strong>The difference between the level of DKK-1 in tumour and NT specimens was not significant for the whole NSCLC group and SCC and LCC subtype, while in AC samples they were significantly higher (<i>p</i> = 0.028). The highest concentration of DKK-1 was found in the advanced NSCLC samples, with the T4 parameter as well as stage III. Significantly decreased DKK-2 concentrations were detected in all NSCLC subtypes (<i>p</i> < 0.05). Moreover, the DKK-2 level was higher in non-smokers than in smokers. The results indicate that concentrations of DKKs were different in relation to subtypes as well as clinical and socio-demographic parameters. The concentration of DKKs could be associated with the progression of NSCLC.</p><p><strong>Conclusions: </strong>We suggest that DKK-1 could play an oncogenic role in AC, while DKK-2 could be a tumour suppressor in all NSCLC subtypes. Dickkopf-1 and DKK-2 proteins could have differential roles in the Wnt signalling pathway, which is important in many cellular processes, such as proliferation and apoptosis.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"28 1","pages":"9-14"},"PeriodicalIF":1.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11117157/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141155478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early growth response 1 transcription factor and its context-dependent functions in glioblastoma.","authors":"Saleh Rasras, Esma'il Akade, Seyed Ehsan Mohammadianinejad, Maedeh Barahman, Mohammad Bahadoram","doi":"10.5114/wo.2024.142583","DOIUrl":"https://doi.org/10.5114/wo.2024.142583","url":null,"abstract":"<p><p>Glioblastoma is the most aggressive form of primary brain tumour in adults. This tumour employs numerous transcription factors to advance and sustain its progression. Current evidence suggest that early growth response 1 (EGR1) plays a dual role as both an oncogene and a tumour suppressor in glioblastoma. Early growth response 1 expression is prevalent in glioblastoma, affecting over 80% of cases. Early growth response 1 regulatory roles extend to angiogenesis, cell adhesion, and resistance to chemotherapy, notably influencing pathways like hypoxia-inducible factor 1α and vascular endothelial growth factor A. Early growth response 1 can also induce cell adhesion, migration, chemoresistance against temozolomide, stemness, and self-renewal in glioblastoma cells. Despite its oncogenic functions, EGR1 can also suppress tumours by upregulating non-steroidal anti-inflammatory drug-activated gene 1 and phosphatase and tensin homolog deleted on chromosome ten, and inhibiting invasion and metastasis. Additionally, EGR1 may have hypothetical implications in the viral hit-and-run theory, particularly regarding cytomegalovirus infection. The key findings of this review are the context- dependent nature of EGR1's actions and its potential as a prognostic marker in glioblastoma. Further research is needed to understand EGR1's role fully and exploit its potential in clinics.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"28 2","pages":"91-97"},"PeriodicalIF":2.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142478916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the perspectives of female cancer patients on the donation of reproductive cells for fertility preservation and research purposes.","authors":"Justyna Czekajewska, Dariusz Walkowiak, Rodryg Ramlau, Jan Domaradzki","doi":"10.5114/wo.2024.144135","DOIUrl":"https://doi.org/10.5114/wo.2024.144135","url":null,"abstract":"<p><strong>Introduction: </strong>This study aims to explore the opinions of female cancer patients regarding the donation of cancer and reproductive cells for reproductive and research purposes.</p><p><strong>Material and methods: </strong>The study involved 373 female cancer patients from 2 hospitals with oncology departments in Poznan, Poland. They completed a pen-and-paper questionnaire-based survey.</p><p><strong>Results: </strong>While most female cancer patients declared their willingness to donate cancer tissues for fertility research (87.9%), they were reluctant to share their reproductive cells for research purposes (82.3%). Additionally, 88.2% of respondents were unwilling to donate embryos that remain after in vitro treatment for research purposes. Simultaneously, 57.1% of woman supported the preservation of fertility cells, 62.5% believed it should be ethically and legally regulated in Poland, and 74% believed it should be re-imbursed by the National Health Fund. Women's opinions were linked to their age, education, place of residence, family status, and declared religiosity.</p><p><strong>Conclusions: </strong>Because most female cancer patients expressed their willingness to share their reproductive cells for reproductive purposes and believed that the preservation of cells for fertility purposes should be reimbursed by the State, there is a need for doctors and nurses to inform patients about the available ways to preserve fertility. However, because donation of reproductive cells for biomedical research raises many concerns, healthcare professionals should be trained to discuss with patients the ethical and legal issues related to fertility preservation and biomedical research involving reproductive cells.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"28 3","pages":"217-226"},"PeriodicalIF":2.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538977/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}